| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.9 | -17.5 |
| EPS (diluted, $ a share) | $-0.03 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ELDN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Eledon Pharmaceuticals, Inc.: key numbers
- Share price
- $1.97Close, Nov 16
- Market cap
- $166M
- Shares outstanding
- 84.46MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Eledon Pharmaceuticals, Inc.
All →Eledon Pharmaceuticals Financial Results
Eledon Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $69.7 million and progress in its tegoprubart clinical program. The company remains on track to initiate its global Phase 3 LEGACY trial in kidney transplantation in Q4 2026 and recently received FDA Fast Track designation for the candidate.
- Term
- Q3 2026
“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end.”
David-Alexandre C. Gros, M.D., Chief Executive Officer